Please use this identifier to cite or link to this item:
https://doi.org/10.1152/ajpheart.00512.2006
DC Field | Value | |
---|---|---|
dc.title | Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction | |
dc.contributor.author | Wang, Y.-X. | |
dc.contributor.author | Ding, Y.-J. | |
dc.contributor.author | Zhu, Y.-Z. | |
dc.contributor.author | Shi, Y. | |
dc.contributor.author | Yao, T. | |
dc.contributor.author | Zhu, Y.-C. | |
dc.date.accessioned | 2016-11-17T08:39:05Z | |
dc.date.available | 2016-11-17T08:39:05Z | |
dc.date.issued | 2007-01 | |
dc.identifier.citation | Wang, Y.-X., Ding, Y.-J., Zhu, Y.-Z., Shi, Y., Yao, T., Zhu, Y.-C. (2007-01). Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. American Journal of Physiology - Heart and Circulatory Physiology 292 (1) : H348-H359. ScholarBank@NUS Repository. https://doi.org/10.1152/ajpheart.00512.2006 | |
dc.identifier.issn | 03636135 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/130601 | |
dc.description.abstract | The intracellular signaling of human urotensin II (hU-II) and its interaction with other vasoconstrictors such as ANG II are poorly understood. In endothelium-denuded rat aorta, coadministration of hU-II (1 nM) and ANG II (2 nM) exerted a significant contractile effect that was associated with increased protein kinase C (PKC) activity and phosphorylation of PKC-α/βII and myosin light chain, whereas either hU-II or ANG II administered alone at these concentrations had no statistically significant effect. This synergistic effect was abrogated by the PKC inhibitor chelerythrine (10 and 30 μM), the selective PKC-α/βII inhibitor Gö-6976 (0.1 and 1 μM), the hU-II receptor ligand urantide (30 nM and 1 μM), or the ANG II antagonist losartan (1 μM). Moreover, in endothelium-intact rat aorta, the synergistic effect of hU-II and ANG II was not exerted any longer, and this synergistic effect was unmasked by pretreatment of the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester. hU-II (10 nM) alone caused a long-lasting increase in phospho-PKC-θ, phospho-myosin light chain, and PKC activity, which was associated with long-lasting vasoconstriction. These changes were prevented by chelerythrine. Methoxyverapamil-thapsigargin treatment reduced the hU-II-induced vasoconstriction by ∼50%. The methoxyverapamil-thapsigargin-resistant component of hU-II-induced vasoconstriction was dose-dependently inhibited by chelerythrine. In conclusion, hU-II induces a novel PKC-dependent synergistic action with ANG II in inducing vasoconstriction. PKC-α/βII is probably the PKC isoform involved in this synergistic action. Nitric oxide produced in the endothelium probably masks this synergistic action. The long-lasting vasoconstriction induced by hU-II alone is PKC dependent and associated with PKC-θ phosphorylation. Copyright © 2007 the American Physiological Society. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1152/ajpheart.00512.2006 | |
dc.source | Scopus | |
dc.subject | Protein kinase C | |
dc.subject | Vascular smooth muscle cells | |
dc.type | Article | |
dc.contributor.department | PHARMACOLOGY | |
dc.description.doi | 10.1152/ajpheart.00512.2006 | |
dc.description.sourcetitle | American Journal of Physiology - Heart and Circulatory Physiology | |
dc.description.volume | 292 | |
dc.description.issue | 1 | |
dc.description.page | H348-H359 | |
dc.description.coden | AJPPD | |
dc.identifier.isiut | 000243383300042 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.